NASDAQ listed companies are sincerely seeking obesity drugs with the potential for weight loss and muscle gain, small molecules are preferred. The specific requirements are as follows:
- Stage: Hit, Lead, PCC, IND-enabling, Phase 1 clinical trial
- Molecular entities: small molecules
- Targets: GLP-1, GIP, GCG, APJ, ACTRIIA, ACTRIIB, etc.
- Rights Interested: Global rights, excluding China rights
- Preferred cooperation model: Licensing
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
Please indicate the project code: BP-20240818-EE-110
We will discuss in detail with you. Thank you!
Contact person: Richard
Phone: 17821449819
WeChat: DrugTimes_BD
Email: BD@drugtimes.cn
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 